Translation Therapeutics Headquarters
Looking for information about Translation Therapeutics Headquarters? The links below have collected all the necessary data.
Anima Biotech: Advancing Translation Control Therapeutics
- https://www.startupcity.com/vendor/anima-biotech-advancing-translation-control-therapeutics-cid-387-mid-41.html
- Headquarters. Bernardsville, NJ and Tel Aviv, Israel. Management. Yochi Slonim, Co-founder and CEO. Description. Anima Biotech is advancing Translation Control Therapeutics, the first and only platform for the discovery of small molecule drugs that control mRNA translation as a new strategy against hard and undruggable targets in many diseases.
Transition Therapeutics - Crunchbase Company Profile & Funding
- https://www.crunchbase.com/organization/transition-therapeutics
- Contact Email [email protected]. Phone Number 416-260-7770. Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND005 for the treatment of Alzheimer's disease and TT223 for the treatment of diabetes.Founded: 1987
Transine Therapeutics LinkedIn
- https://www.linkedin.com/company/transine-therapeutics
- Transine Therapeutics is a private biotechnology company, headquartered in Cambridge-UK, focused on the development of a novel class of therapeutic RNAs that can upregulate protein expression with ...
TTHI Stock Forecast, Price & News (Transition Therapeutics)
- https://www.marketbeat.com/stocks/NASDAQ/TTHI/
- Jul 29, 2021 · Transition Therapeutics' mailing address is 101 College St Suite 220, TORONTO, ON M5G 1L7, Canada. The biopharmaceutical company can be reached via phone at +1-416-2607770.2.9/5
Transition Therapeutics Company Profile: Acquisition ...
- https://pitchbook.com/profiles/company/51085-99
- Post Valuation. Last Financing Details. Developer of therapeutics for disease indications. The company provides a product for the treatment of Alzheimer's disea. Drug Discovery. Toronto, Canada. 18 As of 2015. 000.00. 00.00 0000-00-00.
Contact Us – ADC Therapeutics
- https://www.adctherapeutics.com/contact/
- Translation & Innovation Hub Building. Imperial College White City Campus 84 Wood Lane London, W12 0BZ, UK +44 20 4551 2182. NORTH AMERICA. ... ADC Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma September ...
Working at Transition Therapeutics Glassdoor
- https://www.glassdoor.ca/Overview/Working-at-Transition-Therapeutics-EI_IE27423.11,34.htm
- Revenue: $25 to $50 million (USD) Competitors: UNKNOWN. Transition Therapeutics would like to help people suffering from disease to make the transition to good health. The biotechnology firm is working on therapies to treat metabolic and neurological ailments such as diabetes, Alzheimer's disease, multiple sclerosis, and brain injury ...
PIC Therapeutics - Crunchbase Company Profile & Funding
- https://www.crunchbase.com/organization/pic-therapeutics
- blocking oncogene protein production by modulating the Pre-Initiation Complex (PIC) that drives their mRNA translation. Its selective approach has the potential to simultaneously modulate multiple oncogenic drivers leading to a powerful new generation of cancer-treating therapeutics. PIC Therapeutics was founded in 2016 and is headquartered in
Have you found Translation Therapeutics Headquarters information?
On our site you can find many other information about headquarters of any company. Research information about other companies.